
    
      Secondary objectives

        -  To evaluate the tolerability of V503 in 16- to 26-year-old men.

        -  To summarise humoral immune responses, including anti-HPV 6, 11, 16, 18, 31, 33, 45, 52,
           58 GMTs and seroconversion rates at 4 weeks post-dose 3, in 16- to 26-year-old men who
           received V503 or GARDASIL
    
  